Source disclosure: March 05, 2026, 08:30 JST
Published by Pulse News Wire: March 05, 2026, 08:32 JST
Oncolys BioPharma Inc. [4588.T]
TOKYO, Mar 05 (Pulse News Wire) – Oncolys BioPharma Inc. (4588.T) announced that its licensee, Transposon, was awarded up to from the U.S.
Advanced Research Projects Agency for Health (ARPA-H) to develop OBP-601, a LINE-1 reverse transcriptase inhibitor aimed at extending healthy lifespan through targeted aging research. The funding, part of ARPA-H's PROSPR program, will support research advancements and expenses related to OBP-601.
Dennis Podlesak, CEO of Transposon, highlighted the potential of OBP-601 to pioneer a new therapeutic category addressing the root causes of age-related diseases. Andrew Brack, founder of the PROSPR program, noted the selection based on the connection between increased inflammation with aging and LINE-1 activation.
While there will be no impact on Oncolys' fiscal year ending December 2026 performance, the company expresses significant optimism about Transposon’s progress in developing OBP-601 as a groundbreaking treatment for age-related conditions.
AI-translated content. 🟢 Confidence: High See terms • Original filing